The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy.
- Published In:
- Scientific reports, 14(1), 24433 (2024)
- Authors:
- Kornelius, Edy(3), Huang, Jing-Yang, Lo, Shih-Chang, Huang, Chien-Ning, Yang, Yi-Sun
- Database ID:
- RPEP-08587
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-08587APA
Kornelius, Edy; Huang, Jing-Yang; Lo, Shih-Chang; Huang, Chien-Ning; Yang, Yi-Sun. (2024). The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy.. Scientific reports, 14(1), 24433. https://doi.org/10.1038/s41598-024-75965-2
MLA
Kornelius, Edy, et al. "The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy.." Scientific reports, 2024. https://doi.org/10.1038/s41598-024-75965-2
RethinkPeptides
RethinkPeptides Research Database. "The risk of depression, anxiety, and suicidal behavior in pa..." RPEP-08587. Retrieved from https://rethinkpeptides.com/research/kornelius-2024-the-risk-of-depression
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.